A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Must not have a history of egg allergy or allergic reactions to any component of CHO-H01.
• •Must not have any known or current illnesses (such as autoimmune disease, unless well controlled or resolved), infection, or other condition that could limit study compliance or interfere with assessments.
• •Subjects who have received anti-programmed death-ligand 1 (PD-L1), programmed cell death 1 (PD-1), or cytotoxic T-lymphocyte associated protein 4 (CTLA-4) therapy.
• •Subjects who have completed an autologous stem cell transplant within 100 days prior to CHO-H01 therapy or an allogeneic stem cell transplant.
• •Subjects with known hepatitis B surface antigen (HBsAg) seropositive or known or suspected active hepatitis C infection with detectable viral load.
• •Subjects with known human immunodeficiency virus (HIV) infection
• •Subjects who have had radiation therapy, major surgical procedure or live vaccinations within 28 days prior to CHO-H01 administration.
• •Subjects with a history of type I hypersensitivity or anaphylactic reactions to murine proteins or to previous infusions of CD20 monoclonal antibodies.
• •Subjects who have received (or are receiving) systemic corticosteroids:
• •1. At a daily dose higher than 15 mg prednisone or equivalent within 14 days prior to the first administration of CHO-H01;
• •2. Topical, inhaled, nasal, and ophthalmic steroids are allowed.
• •Inadequate bone marrow, hepatic or renal function.
• •Subjects with a history of seizure disorder.
• •Subjects who are pregnant or breast feeding.
• •Subjects with any contraindications to lenalidomide (Only for phase IIa).